Brief: Bergenbio Announces Launch Of Business Strategy Focused On NSCLC And COVID-19

Oncoinvent ASA

04/05/2022 08:39

May 4 (Reuters) - Bergenbio ASA  BGBIO.OL :
    * ANNOUNCES LAUNCH OF BUSINESS STRATEGY FOCUSED ON NSCLC AND
COVID-19
    * TO FOCUS ON TWO KEY OPPORTUNITIES FOR ITS LEAD COMPOUND
BEMCENTINIB
    * WILL NOW FOCUS ON TWO KEY INDICATIONS; 1ST LINE NON-SMALL
CELL
LUNG CANCER (NSCLC) AND COVID-19

Source text for Eikon:  ID:nObi9DJKJa 
Further company coverage:  BGBIO.OL 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))